Introduction {#s01}
============

Constitutively expressed chemokines control leukocyte trafficking under steady state conditions. These chemokines are crucial for tissue-specific migration and positioning of immune cells within lymphoid organs ([@bib36]). Mice bearing genetic deficiencies of certain homeostatic chemokines or their receptors have marked defects in lymphoid tissue formation and organ development or show increased sensitivity to infections ([@bib13]; [@bib14]; [@bib54]). CCL22 belongs to the group of chemokines that are both constitutively expressed under homeostatic conditions and inducible upon inflammation. The role of inflammatory CCL22 expression is well described: several types of immune cells, such as macrophages, dendritic cells (DCs), B cells, and T cells, secrete CCL22 upon activation ([@bib26]; [@bib50]). CCL22 is induced by LPS, IL-4, and IL-13 and in T cells by TCR stimulation ([@bib18]). The only (so far) known receptor of CCL22 is CCR4, which also interacts with a second ligand, the chemokine CCL17 ([@bib6]; [@bib26]).

Upon immune activation, CCR4 is expressed by T helper 2 (Th2)--activated and memory CD4 T cells. CCR4 expression on activated T cells enables their immigration into the skin, predominantly by interaction with CCL17, which is present on dermal blood vessels in the setting of inflammation ([@bib6], [@bib7]). In contrast to CCL17, no CCL22 is found on skin endothelial cells. Thus, upon dermal inflammation, CCL17 rather than CCL22 promotes Th2 and memory T cell trafficking ([@bib12]). Induction of CCL22 further plays a major role in the pathogenesis of allergy, and high levels are detectable in the lung and the skin in asthma and atopic dermatitis, respectively ([@bib35]). In these diseases, CCL22 attracts activated CCR4-positive Th2 cells that maintain the allergic process.

In the absence of inflammation, the receptor CCR4 is expressed predominantly by regulatory T cells (T reg; [@bib19]), and CCL22 serves as an important factor for the induction of T reg migration in vitro and in vivo ([@bib19]; [@bib38]). In pancreatic islets, for instance, CCL22 recruits T reg and thus delays diabetes ([@bib30]). In cancer, expression of CCL22 is induced in the tumor tissue of many human malignancies and is thought to mediate T reg immigration through CCR4 into the tumor tissue, leading to an inhibition of antitumor immunity ([@bib11]; [@bib45]).

In the lymph node, CCL22 is expressed in large amounts by DCs ([@bib47]); however, the function and role of this central CCL22 expression was so far not known. We demonstrate here that CCL22 expression by DCs induces cellular contacts with T regs through their CCR4 receptor. The formation of a cell contact and the interaction with the DCs is a requirement for the suppression of adaptive immunity through T regs ([@bib48]; [@bib31]; [@bib51]; [@bib37]). In the present study, we show that deficiency of CCL22 results in a reduction of DC--T reg contacts and in a defect of T reg--mediated suppression, as indicated by an unusually potent adaptive immune response upon vaccination, prolonged survival upon tumor vaccination, and increased susceptibility to inflammatory bowel disease.

Results {#s02}
=======

DCs are the exclusive source of homeostatic CCL22 in the lymph node {#s03}
-------------------------------------------------------------------

To quantify the protein expression level of homeostatic CCL22 in different murine organs, tissue lysates were analyzed by ELISA. As expected, the highest expression by far of constitutive CCL22 was observed in the lymph node and the thymus. Moderate CCL22 levels were found in the Peyer's patches, the spleen, the lung, the colon, and the skin, and only minimal expression was seen in all other organs and the serum ([Fig. 1 A](#fig1){ref-type="fig"}, left). A relatively high amount of CCL22-expressing cells in lymph nodes was confirmed by immunohistochemistry ([Fig. 1 A](#fig1){ref-type="fig"}, right). Spontaneous and thus constitutive CCL22 secretion was also observed in vitro: murine splenocytes were cultured without any stimulation, and CCL22 levels were determined in the supernatant at different time points by ELISA. CCL22 secretion was detectable after 12 h, followed by a strong spontaneous secretion during the next 5 d ([Fig. 1 B](#fig1){ref-type="fig"}). To confirm the cellular source of constitutive CCL22 expression in the lymph node, we analyzed its expression by DCs, as these cells are known as major CCL22 producers upon stimulation ([@bib50]). Indeed, quantitative PCR analysis of freshly isolated lymph node CD11c^+^ cells revealed high CCL22 mRNA levels, whereas no CCL22 mRNA was found in the CD11c-depleted fraction ([Fig. 1 C](#fig1){ref-type="fig"}). The same pattern was observed in the spleen, although CCL22 levels were considerably lower than in the lymph node. Within the different DC subtypes, in particular CD103^+^ DCs express CCL22, whereas only low levels were detectable on CD11b^+^ or B220^+^ plasmacytoid DCs ([Fig. 1 D](#fig1){ref-type="fig"}).

![**CCL22 is constitutively expressed in vivo and in vitro. (A)** CCL22 protein was quantified in tissue homogenates and in the serum of BALB/c mice by ELISA (*n* = 5 mice) and detected by immunohistochemistry in the lymph node (LN). PP, Peyer\'s patches. Bar, 100 µm. **(B)** 10^6^ freshly isolated lymph node cells and splenocytes from C57BL/6 mice were cultured, and CCL22 levels in the supernatants were determined at different time points by ELISA. **(C)** CCL22 mRNA expression from unsorted, CD11c-depleted (CD11c^−^), or CD11c-enriched (CD11c^+^) murine lymph node cells or splenocytes was determined by quantitative real-time PCR. **(D)** CD11b^+^CD8^neg^, CD11b^neg^CD8^+^, B220^+^, CD103^+^, and CD103^neg^ cells were sorted from CD11c-enriched splenocytes, and RNA was isolated followed by quantitative real-time PCR. **(E)** CCL22 protein level in intestinal or skin-draining lymph node tissue homogenates of C57BL/6 mice measured by ELISA (*n* = 3 mice). **(F)** 10^5^ freshly isolated CD11c^+^ splenic DCs or 7-d differentiated BMDCs from C57BL/6 mice were cultured with or without 3 µg/ml CpG for 4 h, and CCL22 levels in the supernatants were determined by ELISA. Data are presented as mean ± SEM and are representative of two to four independent experiments (*n* = 3--5 mice per group). \*\*\*, P \< 0.001 (two-sided Student's *t* test).](JEM_20170277_Fig1){#fig1}

Further, higher levels were seen in CD8^+^CD11b^neg^ so-called lymphoid DCs. Interestingly, DCs in intestinal lymph nodes expressed twofold higher levels of CCL22 than did those within skin-draining lymph nodes ([Fig. 1 E](#fig1){ref-type="fig"}). This is consistent with previous data comparing chemokine expression profiles in splenic and lymph node DCs ([@bib49]; [@bib16]) and fits with transcriptional data from the ImmGen database. In vitro, CCL22 is secreted by both CD11c^+^ DCs that are obtained from freshly isolated lymphoid tissue and by bone marrow--derived DCs (BMDCs) that are generated by culture in the presence of IL-4 and GM-CSF. Notably, stimulation of both types of DCs by CpG as activator of Toll-like receptor 9 strongly enhanced CCL22 secretion ([Fig. 1 F](#fig1){ref-type="fig"}). Taken together, these data show that DCs are the exclusive producers of constitutive CCL22 in the lymph node and the spleen under steady state conditions.

Next, we aimed to determine the cell types responding to CCL22 under homeostatic conditions. The only receptor known so far for CCL22 is CCR4 ([@bib20]). In freshly isolated naive splenocytes, we detected CCR4 expression predominantly by CD4^+^Foxp3^+^ T regs and, within those, particularly in memory T regs (Fig. S1 A), which is in accordance with previous reports ([@bib19]). Further, within unstimulated leukocytes, CCL22 selectively attracted Foxp3^+^ T regs in a standard migration assay (Fig. S1 B). In conclusion, under homeostatic conditions, CCL22 in the lymph node is expressed exclusively by DCs, and the responder cells carrying the cognate receptor CCR4 are T regs.

CCL22 mediates DC--T reg contacts in vitro and in vivo {#s04}
------------------------------------------------------

It is well established that DC--T reg contacts are critically important for immune regulation by T regs ([@bib48]; [@bib31]; [@bib51]; [@bib37]). We hypothesized that DC-derived homeostatic CCL22 attracts T regs to establish DC--T reg contacts. To address this question, we used DCs derived from CCL22-deficient mice. The so far uncharacterized *Ccl22^−/−^* mouse was recently generated by the National Institutes of Health (NIH) Knockout Mouse Project. As expected, no CCL22 protein was detectable in any of the analyzed tissues of *Ccl22^−/−^* mice, and no CCL22 secretion was observed in vitro (Fig. S2, A and B). Further, no obvious phenotypical differences were observed compared with WT mice in terms of weight and morphology of lymphoid organs, as well as for the proportion of immune cell subsets (data not shown). We generated BMDCs from WT and *Ccl22^−/−^* mice and used the supernatants as chemoattractants in a standard migration assay with splenocytes as responder cells. Medium from WT DCs induced specific T reg migration, which was abolished in medium from *Ccl22^−/−^* DCs (Fig. S3 A).

Next, we isolated CD11c^+^ DCs from *Ccl22^−/−^* and WT mice, pulsed them with the OVA~323--339~ peptide, and cocultured them with antigen-specific red-labeled T regs (CD3^+^CD4^+^CD25^+^) and green-labeled conventional CD4 T cells (T convs; CD3^+^CD4^+^CD25^neg^) derived from OT-II transgenic mice. As previously described, when a mixture of T regs and T convs at a 1:1 ratio is used in this assay, T regs outcompete T convs for space on the DCs ([@bib31]). Indeed, we detected on average three times more T regs than T convs on the surface of WT DCs, while the overall number of T cells in contact with the DCs remained unchanged ([Fig. 2 A](#fig2){ref-type="fig"}). In striking contrast, equal numbers of T regs and T convs were observed when *Ccl22^−/−^* DCs were used. These findings suggest that the dominance of T regs over T convs in terms of interaction with the DCs depends on DC-derived CCL22.

![**CCL22 mediates DC--T reg contacts. (A)** T convs (green) and T regs (red) from OT-II mice were mixed at a 1:1 ratio and cultured with unlabeled *Ccl22^−/−^* or C57BL/6 WT CD11c^+^ splenic DCs in the presence of 1 µg/ml OVA~323--339~ peptide. After 12 h, cells were imaged by confocal microscopy (representative images are shown; bars, 15 µm), and the ratio of T regs to T convs per DC cluster was determined. **(B)** 10^6^ T convs or T regs (both red) from C57BL/6 mice were mixed in a collagen gel with 10^5^ BMDCs (green) from *Ccl22^−/−^* or WT mice, and DC--T cell interaction was analyzed by confocal microscopy over 8 h. Resulting videos were analyzed for DC--T cell contacts by a computer algorithm. Left: One dot represents the percentage of DCs in contact with T cells at one time point. Right: Triplicates of the respective conditions were cocultured in parallel. One dot represents the mean percentage of DCs in contact with T cells over the total culture time. **(C)** BMDCs were treated with either control or CCL22 siRNA and, as in B, mixed with T regs, and DC--T cell interaction was quantified. **(D)** DC--T cell interaction was analyzed and depicted as in B, and DC2.4-CCL22^dox^ cells in which CCL22 is inducible by doxycycline (Dox) were used. **(E)** Differently labeled OVA~323--339~-pulsed BMDCs were pretreated with control or CCL22 siRNA 18 h before injection into the footpad of OT-II-Foxp3-GFP mice. The footpad-draining lymph node was imaged by two-photon microscopy (a representative image of a 1-h video is shown; bar, 30 µm), and the number of OT-II-Foxp3^+^--T reg contacts with DCs per hour as well as the contact time for each T reg--DC contact was quantified by two blinded independent investigators. 15 control DCs and 16 CCL22 knockdown DCs were examined. The instantaneous velocities were calculated from manually tracked cells using Imaris. All in vitro data are representative of three and all in vivo data of two independent experiments. Data are shown as mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; ns, not significant (two-sided Student's *t* test).](JEM_20170277_Fig2){#fig2}

To further assess the role of CCL22 in the interaction of DCs with T regs, we set up a three-dimensional (3D) assay using a collagen gel matrix with live-cell imaging by confocal laser microscopy. Both DCs and T cells moved in the gel, with more rapid movements observed for T cells. In a typical assay with T cells and DCs, ∼50% of the cells were motile, with an average velocity up to 2.6 µm/min (Video 1). Contacts between DCs and T cells were observed frequently, with a mean duration of 22 min. We embedded red dye--labeled naive WT T regs or T convs with green dye-labeled DCs from either *Ccl22^−/−^* or WT mice in the collagen matrix and quantified DC--T cell contacts. CCL22-deficient DCs established significantly less contacts with T regs, whereas no difference was observed with T convs ([Fig. 2 B](#fig2){ref-type="fig"} and Videos 2, 3, 4, and 5). Similar results were obtained by knocking down CCL22 in WT DCs with CCL22 siRNA ([Figs. 2 C](#fig2){ref-type="fig"} and S3 B).

We next analyzed the effects of CCL22 overexpression on DC--T reg contacts. For this purpose, we used a myc- and raf-immortalized DC cell line ([@bib43]) transduced with a lentiviral construct containing CCL22 downstream of a Tet-responsive element and rtTA under the control of a CMV promoter. These cells (DC2.4-CCL22^dox^) were unable to produce CCL22 even in the presence of T cells, but CCL22 was strongly inducible by addition of doxycycline (Fig. S3 C). We then mixed DC2.4-CCL22^dox^ cells with T regs or T convs in a collagen gel in the presence or absence of doxycycline. As expected, treatment of DC2.4-CCL22^dox^ cells with doxycycline induced CCL22 secretion by DCs (Fig. S3 C) and increased the frequency of DCs in contact with T regs, whereas no increase was seen for DCs and T convs ([Fig. 2 D](#fig2){ref-type="fig"} and Videos 6, 7, 8, and 9). To demonstrate that the CCL22-induced DC--T reg contacts are mediated by CCR4 on T regs, we repeated the assay with T regs from CCR4-deficient mice. Indeed, CCR4-deficient T regs did not enhance their contact frequency with DCs upon doxycycline-induced up-regulation of CCL22, indicating that CCL22--CCR4 interaction is required for this process (Fig. S3 D).

To demonstrate that CCL22 is important for DC--T reg contacts in vivo, we imaged the interaction of both cells in the lymph node by two-photon intravital microscopy: OVA~323--339~ peptide-pulsed CCL22-deficient and CCL22-expressing DCs labeled with different dyes were injected into the footpad of transgenic OT-II-Foxp3-GFP mice in which CD4^+^ T cells recognize the OVA peptide and T regs express GFP. The footpad-draining popliteal lymph node was then imaged by two-photon microscopy, and DC--T reg contacts were quantified (Video 10). Indeed, CCL22-expressing DCs formed significantly more and longer contacts with T regs than CCL22-deficient DCs ([Fig. 2 E](#fig2){ref-type="fig"}). The distribution of either DC population in the T cell zones of the draining lymph node was similar, as was their instantaneous velocity. Taken together, these data show that homeostatic expression of CCL22 by DCs mediates the formation of DC--T reg contacts that are known to be critical for T reg function.

Vaccination leads to excessive T cell immunity in Ccl22^−/−^ mice {#s05}
-----------------------------------------------------------------

Less DC--T reg interaction should alter T reg function. As in vivo suppression by T regs can be assessed by the extent of a defined T cell immune response, *Ccl22^−/−^* and WT mice were vaccinated with OVA. Strikingly, OVA-specific cytotoxic T cells (CTLs) were on average more than doubled in *Ccl22^−/−^* mice compared with WT mice, and 2.7-fold more IFN-γ--positive CTLs were detectable upon in vitro restimulation ([Fig. 3, A and B](#fig3){ref-type="fig"}). Indeed, in some *Ccl22^−/−^* mice, up to 23% of antigen-specific CD8 T cells were observed. Similar findings were observed for CD4^+^ OVA-specific T cells (Fig. S3 E). Thus, deficiency of CCL22 strongly enhances the T cell response upon immunization, supporting the concept of reduced T reg suppression. Interestingly, no difference in the amount of OVA-specific antibodies was detected in *Ccl22^−/−^* and WT mice upon vaccination, indicating that the humoral response may not be regulated by CCL22 (data not shown).

![***Ccl22^−/−^* mice have excessive T cell responses upon vaccination.** *Ccl22^−/−^* and WT C57BL/6 mice were injected with OVA protein two times at a 7-d interval, and CpG together with Alum were used as adjuvant. **(A and B)** 1 wk after the last injection, the frequency of OVA-specific cytotoxic T cells (CD19^neg^CD3^+^CD8^+^) in the peripheral blood was determined by pentamer (H-2Kb OVA~257--264~) staining (A) and intracellular IFN-γ staining (B) upon restimulation with OVA~257--264~ peptide (*n* = 11 mice per group treated with OVA and *n* = 4 mice per group without treatment). Data are shown as mean ± SEM and are pooled from two independent experiments. In total, three experiments with similar results were performed. \*\*, P \< 0.01 (two-sided Student's *t* test).](JEM_20170277_Fig3){#fig3}

Ccl22^−/−^ DCs induce stronger adaptive immune responses {#s06}
--------------------------------------------------------

We next wanted to provide evidence that the strong immune response in *Ccl22^−/−^* mice was indeed due to CCL22 deficiency in the DCs. Toward this aim, we vaccinated C57BL/6 WT mice with either WT or *Ccl22^−/−^* DCs that were pulsed with OVA~257--264~ peptide and quantified T cell immunity. Mice were injected with peptide-pulsed DCs every second week, and 1 wk after the third immunization, the frequency of OVA~257--264~-specific T cells and the extent of the IFN-γ response upon in vitro restimulation were quantified. Strikingly, vaccination of WT mice with DCs derived from *Ccl22^−/−^* mice induced substantially stronger T cell immune responses compared with WT DCs: the frequency of antigen-specific and IFN-γ--positive T cells was more than doubled in mice treated with *Ccl22^−/−^* DCs ([Fig. 4 A](#fig4){ref-type="fig"}). Interestingly, DCs from *Ccl22^−/−^* mice did not show any differences from WT DCs in terms of in vivo migration, survival, costimulatory molecule expression, or antigen-presentation potential as well as cross-presentation (Fig. S4, A--C). Further, the secretion of proinflammatory cytokines was not altered in *Ccl22^−/−^* DCs (Fig. S4 D). These findings indicate that the CCL22 production by DCs is important for limiting immune responses against non-self-antigens. To assess the contribution of CCR4 to CCL22-mediated immune regulation, we immunized CCR4-deficient (*Ccr4^−/−^*) mice with OVA~257--264~-pulsed *Ccl22^−/−^* or WT DCs and quantified T cell immunity. Interestingly, the dominance of *Ccl22^−/−^* over WT DCs in terms of T cell immune response induction was lost in CCR4-deficient mice, demonstrating that CCL22 regulates T cell immunity through CCR4 ([Fig. 4 B](#fig4){ref-type="fig"}). Finally, it was remarkable that the immune responses were generally stronger in CCR4-deficient mice, which is in line with our hypothesis that the CCL22--CCR4 axis regulates T cell immunity.

![**CCL22-deficient DCs strongly increase T cell immunity. (A)** OVA~257--264~-pulsed *Ccl22^−/−^* or WT DCs were injected into C57BL/6 WT mice three times every 14 d, and CpG together with Alum were used as adjuvant (*n* = 15 mice per group injected with DCs and *n* = 4 mice without treatment). The frequency of splenic OVA-specific cytotoxic T cells was determined by pentamer (left) and intracellular IFN-γ staining (right) as described in [Fig. 3](#fig3){ref-type="fig"} 1 wk after the last injection. Data are shown as mean ± SEM and are pooled from two independent experiments. In total, four experiments with similar results were performed. **(B)** OVA~257--264~-pulsed *Ccl22^−/−^* or WT DCs were injected into either *Ccr4^−/−^* or WT recipient mice. The experiment was performed as described in A (*n* = 7 mice per group injected with DCs and *n* = 2 mice per group without treatment). Data are shown as mean ± SEM and are representative of two independent experiments. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (two-sided Student's *t* test).](JEM_20170277_Fig4){#fig4}

Ccl22^−/−^ mice show prolonged survival upon vaccination {#s07}
--------------------------------------------------------

T regs are critically involved in regulating the immune response against tumors. In the lymph node, T regs inhibit the initiation of an antitumor immune response, and in the tumor tissue, they locally suppress the infiltrating effector T cells ([@bib55]). To investigate the antitumor immune response in CCL22-deficient mice, we induced subcutaneous tumors that express the OVA antigen (Panc02-OVA-tumors). Mice were vaccinated with OVA protein 1 wk after tumor induction. In *Ccl22^−/−^* mice, we observed a significant reduction of tumor growth ([Fig. 5 A](#fig5){ref-type="fig"}) and increased survival compared with vaccinated WT mice ([Fig. 5 B](#fig5){ref-type="fig"}). A strongly increased OVA-specific T cell response was further observed in tumor-bearing *Ccl22^−/−^* mice compared with the WT animals ([Fig. 5 C](#fig5){ref-type="fig"}). CCL22 was highly expressed in the tumor tissue of WT mice but was undetectable in *Ccl22^−/−^* mice, indicating that intratumoral CCL22 was secreted uniquely by host-derived tumor-infiltrating cells (Fig. S5 A). Surprisingly, the percentage of intratumoral T regs was not significantly lower in *Ccl22^−/−^* mice, indicating that tumor rejection is not a consequence of reduced T reg infiltration and that other factors than CCL22 promote T reg infiltration in this model (Fig. S5 B). In addition, lymphocyte subpopulations and proliferation of cytotoxic T cells in terms of Ki67 expression in tumor and lymph nodes were not altered in *Ccl22^−/−^* mice, suggesting that T cell activation rather than quantity is enhanced by CCL22 deficiency (Fig. S5 B; data on Ki67 expression not shown). In conclusion, CCL22 regulates antitumor immunity, most likely by inhibiting T cell priming in the lymph node.

![**Vaccination against tumors is more efficient in *Ccl22^−/−^* mice. (A and B)** *Ccl22^−/−^* and WT C57BL/6 mice were injected subcutaneously with Panc02-OVA tumors. 1 wk after tumor induction, mice were vaccinated twice with OVA at a 7-d interval as described in [Fig. 3](#fig3){ref-type="fig"}, and tumor size as well as survival was monitored (*n* = 14 mice per group). Growth curves are depicted up to the time point of \>20% deaths in one group. Data are shown as mean ± SEM and are pooled from two independent experiments. In total three experiments with similar results were performed. **(C)** 1 wk after the last vaccination, OVA-specific T cells in the peripheral blood of the mice (*n* = 8, one of three experiments with similar results) were determined as described in [Fig. 3](#fig3){ref-type="fig"}. Data are shown as mean ± SE. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (two-sided Student's *t* test and two-way ANOVA).](JEM_20170277_Fig5){#fig5}

CCL22-deficient mice are more susceptible to inflammatory bowel disease {#s08}
-----------------------------------------------------------------------

We finally aimed to examine whether CCL22-dependent immune regulation also controls inflammatory processes. We chose the dextran sodium sulfate (DSS)--induced colitis model in which bowel inflammation is induced by innate immune activation but is controlled by T regs ([@bib4]). When mice were fed with the standard dose of 2% DSS, both *Ccl22^−/−^* and WT mice developed severe colitis (data not shown). We next used a DSS concentration of 0.5% that was insufficient to induce colitis in WT mice. Strikingly, whereas WT mice did not show any signs of colitis, *Ccl22^−/−^* mice were still severely affected by the disease. This was determined by the clinical disease activity score composed of weight loss, diarrhea, and the detection of blood in the stool, as well as by scoring mucosal destruction and leukocyte infiltration and by inflammation-induced reduction of the colon length ([Fig. 6, A--D](#fig6){ref-type="fig"}). In conclusion, *Ccl22^−/−^* mice are more susceptible to DSS-induced colitis, suggesting that CCL22 may be critically involved in the prevention of inflammatory diseases.

![***Ccl22*-deficient mice are highly susceptible to DSS-induced colitis.** *Ccl22^−/−^* and WT C57BL/6 mice were fed with or without 0.5% DSS dissolved in tap water over a period of 1 wk followed by 1 wk of recreation, in three consecutive cycles. Disease severity was analyzed at day 7 after the last cycle of DSS administration. **(A)** Loss of body weight, diarrhea, and the presence of occult or overt blood in the stool was used to determine the clinical disease activity index (DAI). **(B--D)** The colon length was measured (B) and tissue sections of the colon were analyzed for mononuclear and neutrophilic cell infiltration, crypt hyperplasia, epithelial injury, and crypt abscesses (C and D) to determine the histological score (bars, 200 µm). Data are shown as mean ± SEM of five mice per group and are representative of three independent experiments. \*\*\*, P \< 0.001 (two-sided Student's *t* test).](JEM_20170277_Fig6){#fig6}

Discussion {#s09}
==========

Constitutively expressed chemokines have essential roles in the organism, and most of them, such as CCL21 or CXCL12, have been characterized in detail for their specific functions ([@bib13]; [@bib39]). The functional role of CCL22 expression in lymphoid organs has so far been unknown, although its strong constitutive expression in the lymph node and the thymus has been described previously ([@bib40]; [@bib47]). We show here that CCL22 expression by DCs in secondary lymphoid organs serves as a mediator for DC--T reg contacts that are crucial for immune regulation by T regs. As a functional consequence of CCL22 deficiency, we found overwhelming T cell immunity upon vaccination, enhanced responses against tumors, and stronger inflammatory responses.

Under steady state conditions in the lymph node, CCL22 is expressed at high levels exclusively by DCs, and the corresponding receptor, CCR4, is expressed specifically by T regs. Interestingly, CCL22 expression was predominantly seen in CD103^+^ and CD11b^−^CD8^+^ DCs, which are both known for their potential to induce tolerance, further suggesting a role for immune regulation ([@bib28]). One could speculate on other functional consequences, beyond induction of DC--T reg contacts, of this distinct chemokine and cognate chemokine receptor expression: T regs could be attracted to lymphoid tissues via the CCL22--CCR4 axis; however, we found that in *Ccl22^−/−^* mice, homing of T regs to the lymph node or the spleen was not altered. Further, in *Ccl22^−/−^* mice, T regs were regularly located in the T cell areas with no difference from WT mice (data not shown). It is known that T regs use other receptors, such as CCR7 ([@bib41]), to enter the lymph node, although synergy of chemokine receptors can be required for efficient organ homing ([@bib42]; [@bib15]). However, in a mixed bone marrow chimeric mouse with a WT and a CCR4-deficient donor, no disadvantage of CCR4-deficient T regs was observed in terms of homing to the spleen or the lymph node ([@bib38]). Taken together, these data show that CCL22-CCR4 interaction seems to be dispensable for homing of T regs to the lymph nodes.

Beside their function in mediating tissue immigration, chemokines can also act locally to establish cell--cell interactions ([@bib52]; [@bib8]; [@bib34]). We demonstrate here that CCL22 secretion by DCs indeed induces the formation of cell contacts with T regs in vitro and in vivo. Importantly, this cellular interaction was dependent on CCR4 expression by T regs and was not seen for other T cells. We further show that CCL22 is required for T regs to outcompete T effector cells for space around the DCs, a process that is important for suppression by T regs ([@bib46]; [@bib31]). In general, cellular interaction of T regs with DCs is crucial for the immunosuppressive function of T regs ([@bib29]; [@bib48]; [@bib31]; [@bib51]; [@bib37]). In consequence, a selective deficiency of CCL22 in DCs strongly enhanced immunity upon vaccination, reflected by a more than twofold higher frequency of antigen-specific CD8^+^ T cells. Thus, constitutive CCL22 expression by DCs regulates the adaptive immune response, most likely through the induction of DC--T reg contacts.

We could show here that the CCL22-induced formation of DC--T reg contacts and the resulting strong induction of T cell immunity are dependent on CCR4 expression by T regs. Interestingly, whereas no direct phenotype can be seen in *Ccr4^−/−^* mice, severe autoimmunity occurs when CCR4 is selectively absent on Foxp3^+^ T regs ([@bib38]). Further, CCR4-deficient T regs fail to protect *Rag2^−/−^* recipient mice from CD4^+^CD25^−^CD45RB^high^ T cell transfer colitis ([@bib53]), and CCR4 antagonists can diminish T reg function ([@bib3]; [@bib33]). We demonstrate here that *Ccl22^−/−^* mice are markedly more susceptible to DSS-induced colitis, and as T regs control disease activity in this model ([@bib4]), we predict that reduced CCL22-dependent DC--T reg interaction enhances inflammation. Although a key contribution of CCL22--CCR4 interaction in immune regulation by T regs seems unquestionable, it remains unclear why *Ccl22^−/−^* and *Ccr4^−/−^* mice display no spontaneous autoimmunity. This needs further careful observation and may also be influenced by age, genetic background, or even the microbiome. In addition, other factors, such as CCR5 or CCR7 ligands, can also induce T cell and thus T reg migration and may partially substitute for CCL22 deficiency. Further, contacts with DCs can be stabilized through T cell receptor signaling on T regs ([@bib25]). Thus, under steady state conditions, deficiency of CCL22 may be compensated for by other factors that appear, however, not to be sufficient to prevent autoimmunity in the presence of appropriate triggers. Here, it will also be interesting to analyze the regulation process of CCL22 expression itself in the presence of different triggers, such as Toll-like receptor stimulation, e.g., in infection or autoimmune disease. Taken together, our data show that expression of CCL22 by DCs contributes to T reg--mediated immune suppression and prevents inflammatory immune responses.

In consideration of the crucial role of CCL22 in immune regulation, an important question is whether CCL17, the second ligand for CCR4, exerts similar functions. Intriguingly, however, in *Ccl17^−/−^* mice, DSS-induced colitis was strongly attenuated and *Ccl17^−/−^*/*Rag-1^−/−^* mice were even protected from T cell (CD45RB^high^) transfer-induced colitis ([@bib17]). A functionally different role of both chemokines was further seen in models of cardiac allograft transplantation: whereas allograft survival in *Ccr4^−/−^* mice was decreased ([@bib24]), it was increased in *Ccl17^−/−^* mice ([@bib1]), indicating that CCL17 rather promotes the immune response. Thus, although the chemokines CCL17 and CCL22 are structurally related, their mode of action is different. Homeostatic CCL17 expression in secondary lymphoid organs exists, but we show here that it is 10-fold lower compared with CCL22 (Fig. S2 A). In addition, the receptor CCR4 binds with a threefold lower affinity to CCL17 than to CCL22 ([@bib20]). Thus, we conclude that CCL17 does not substantially act on T regs, at least not in lymph nodes under homeostatic conditions. Moreover, using CCL17-deficient cells, it has been shown that CCL17 boosts LPS-induced proinflammatory cytokine production in an autocrine manner through direct action on the CCR4 receptor of DCs ([@bib17]). Using CCL22-deficient DCs, we did in contrast not detect any effects of CCL22 on cytokine production (Fig. S4 D). These findings may in addition explain the remarkable differences between the two chemokines.

We show here that an exclusive deficiency of CCL22 potently enhances the adaptive immune response induced by vaccination and leads to robust antitumor immune responses. Therapeutic targeting of T regs to enhance the immune response to cancer or infections has been and is subject of numerous studies ([@bib10]). This approach is limited by the lack of specific target molecules on T regs ([@bib44]) and by the fact that complete elimination of T regs will cause severe autoimmunity ([@bib22]). As DC--T reg interaction is critical for T reg--mediated suppression, targeting the involved pathways, rather than the T reg itself, represents a promising novel strategy. In studies by [@bib21], an anti-CCR4 antibody was used to target both CCR4-expressing malignant lymphocytes and T regs, leading to better tumor control. Our data suggest that targeting the CCL22--CCR4 axis could not only deplete T regs but rather inhibit their interaction with DCs, resulting in stronger immunity. Today we have a new class of drugs, the immune checkpoint inhibitors that modulate key pathways in the interaction of T cells with DCs and other target cells and exert powerful immune activation ([@bib32]): Ipilimumab blocks the interaction of CTLA-4 on T regs and T effector cells with CD80 and CD86 on DCs and thus strongly enhances T cell immunity. Blockade of the interaction of PD-1 on T effector cells with PD-L1 on DCs or tumor cells potently activates adaptive immunity. Several PD-1 or PD-L1 blocking antibodies are approved for the treatment of different types of cancer ([@bib5]; [@bib23]). A limitation of the so far available immune checkpoint inhibitors is the induction of autoimmunity. We suggest that the CCL22--CCR4 axis also represents an immune checkpoint and that targeting CCL22 interaction with its receptor could represent a powerful and potentially less harmful therapeutic strategy. In summary, we identified here CCL22 as an important novel regulator of adaptive immunity with impact on vaccine development, host response against cancer, and inflammation.

Material and methods {#s10}
====================

Mice and cell lines {#s11}
-------------------

Female C57BL/6 and BALB/c mice were purchased from Janvier. CCL22 knockout (*Ccl22^−/−^*) mice on the C57BL/6 background were obtained from the NIH-founded Knockout Mouse Project. The CCL22 knockout was achieved by CCL22 gene deletion through homologous recombination using a lacZ neomycin reporter vector. PCR was used to identify homozygous *Ccl22^−/−^* mice. Mice transgenic for a chicken OVA~323--339~-specific T cell receptor (OT-II) were purchased from the Jackson Laboratory. *Ccr4^−/−^* mice on the C57BL/6 background were a gift from Anne Krug (Institute of Immunology, Ludwig-Maximilians-Universität München, Munich, Germany). OTII-Foxp3-GFP mice on the C57BL/6 background were a gift from Vijay Kuchroo (Evergrande Center for Immunologic Diseases at Harvard Medical School, Boston, MA). Mice were 5--10 wk of age at the onset of experiments. Transgenic mice bred in-house and C57BL/6 control mice purchased from Janvier were housed together before being used in experiments. Animal studies were approved by the local regulatory agency (Regierung von Oberbayern, Munich, Germany). The OVA-transfected murine pancreatic cancer cell line Panc02-OVA was a gift from Max Schnurr (Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany). HEK293T cells were obtained from ATCC, and the murine immortalized DCs line DC2.4 was kindly provided by K. Rock (Department of Pathology, University of Massachusetts, Worcester, MA). Cell lines were authenticated using STR (LGC Standards) and were cultured in complete DMEM or RPMI medium (PAA Laboratories) and routinely tested for mycoplasma contamination by MycoAlert Mycoplasma Detection Kit (Lonza). The DC2.4-CCL22^dox^ cell line was generated by lentiviral transduction with a construct containing a doxycycline-inducible CCL22 expression cassette as described ([@bib2]). Syngeneic tumors were induced by subcutaneous injection of 0.5 × 10^6^ tumor cells into the right flank of C57BL/6 or *Ccl22^−/−^* mice. The sample size of each experiment was chosen according to previous experience conducting similar experiments. All animal experiments were randomized, and tumor growth was measured by investigators blinded to the group allocation.

Cytokine assays of tissue lysates {#s12}
---------------------------------

Tissue homogenates were resuspended in lysis buffer (Bio-Rad Laboratories) and centrifuged. Total protein concentration was measured by Bradford assay (Bio-Rad Laboratories). All samples were diluted to a protein concentration of 10 mg/ml, and CCL22 or CCL17 was measured by ELISA (R&D Systems). The final cytokine concentration was calculated as nanograms of cytokine per gram of protein in the respective lysate.

Immunohistochemistry {#s13}
--------------------

For analysis of CCL22 expression from formalin-fixed, paraffin-embedded murine tissue, 3-µm slices were deparaffinized, rehydrated, and heated in Tris-EDTA buffer, pH 9.0, supplemented with 0.5% Tween-20. CCL22 was detected using a rabbit monoclonal anti-CCL22 antibody (ab124768; Abcam) at a dilution of 1:200. After a 1-h incubation period with a secondary HRP-conjugated anti-rabbit antibody (ab205718; Abcam) at a dilution of 1:2,000, staining was performed using 3,3-diaminobenzidine substrate solution. The slices were counterstained with hematoxylin.

Monoclonal antibodies and flow cytometry {#s14}
----------------------------------------

CD3e-APC or CD3e-PE (clone 145-2C11), CD4-APC/Cy7 or CD4-PerCp (clone GK1.5), CD8α-APC/Cy7 or CD8α-PacBlue (clone 53--6.7), CD11c-APC or CD11c-PE (clone N418), CD11b-PerCP (clone M1/70), CD19-PerCP/Cy5.5 (clone HIB19), CCR4-APC or CCR4-PE/Cy7 (clone 2G12), CD25-PE (clone PC61), IFN-γ-Pacific Blue (clone XMG1.2), and Foxp3-Pacific Blue (clone MF-14) were all from BioLegend. T regs were stained with a Foxp3 Staining Buffer Set (eBioscience) according to the manufacturer's instructions. For intracellular IFN-γ staining, peripheral blood or splenocytes were incubated with red blood cell lysis buffer (BD Pharm Lyse; BD Bioscience) for 3 min. Lymphocytes were then stimulated with 100 nM OVA~257--264~ peptide or OVA~323--339~ peptide (both InvivoGen) for 1 h at 37°C before 1 µg/ml brefeldin A (Sigma-Aldrich) was added. After 3 h, cells were surface stained with CD8-APC/Cy7 and CD19-PerCP, then fixed and permeabilized using the Foxp3 Staining Buffer Set (eBioscience) and incubated with an anti--IFN-γ-Pacific Blue antibody. Pentamer staining was performed with H-2Kb OVA~257--264~ R-PE pentamers (ProImmune) according to the manufacturer's instructions. Events were measured on a FACS Canto II flow cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar).

Cell sorting {#s15}
------------

CD11c, B220, CD103, CD8, and CD49b splenic and lymph node cell isolation from WT and *Ccl22^−/−^* mice was performed by one-step magnetic cell sorting (Miltenyi Biotec) or on an Aria II cytometer. CD4^+^CD25^+^ cells and CD4^+^CD25^neg^ cells were purified from the spleen and lymph nodes of WT or OT-II mice by two-step magnetic cell sorting (Miltenyi Biotec). Purity of sorted cells was on average \>90%.

RNA isolation and quantitative PCR analysis {#s16}
-------------------------------------------

Total RNA was extracted from sorted and unsorted single-cell suspensions using the High Pure RNA Isolation Kit (Qiagen) according to the manufacturer's instructions. 1 µg of RNA was converted into cDNA using the Revert Aid First Strand cDNA Synthesis Kit (Fermentas). Quantitative real-time PCR amplification was performed with the Light Cycler TaqMan Master (Roche Diagnostics) on a LightCycler 2.0 instrument (Roche Diagnostics) together with the Universal Probe Library System (Roche Diagnostics; CCL22 probe \#84, hypoxanthine phosphoribosyltransferase \[HPRT\] probe \#69, β-actin probe \#64). Relative gene expression is shown as a ratio of the CCL22 mRNA expression level to the expression level of HPRT or β-actin mRNA. The primers for CCL22 (forward: 5′-TCT​TGC​TGT​GGC​AAT​TCA​GA-3′; reverse: 5′-GAG​GGT​GAC​GGA​TGT​AGT​CC-3′), HPRT (forward: 5′-GGA​GCG​GTA​GCA​CCT​CCT-3′; reverse: 5′-CTG​GTT​CAT​CAT​CGC​TAA​TCA​C-3′), and β-actin (forward: 5′-CTA​AGG​CCA​ACC​GTG​AAA​AG-3′; reverse: 5′-ACC​AGA​GGC​ATA​CAG​GGA​CA-3′) were obtained from Metabion.

Generation of BMDCs {#s17}
-------------------

Bone marrow cells of WT and *Ccl22^−/−^* mice were isolated from the femur and tibia bones. After incubation with red blood lysis buffer, cells were diluted to 10^6^ cells/ml in RPMI 1640 medium supplemented with 10% FBS (Gibco), 1% [l]{.smallcaps}-glutamine, 1 U/ml penicillin, 0.1 mg/ml streptomycin (all PAA), 20 ng/ml GM-CSF, and 20 ng/ml IL-4 (both PeproTech). BMDCs were harvested on day 7.

Chemokine knockdown by siRNA {#s18}
----------------------------

WT BMDCs were transfected (Amaxa nucleofector system; Y-001 immature DC program) at a cell number of 10 × 10^6^ with 10 ng CCL22 siRNA (Mm_Ccl22_3 FlexiTube siRNA; Qiagen) or control siRNA (AllStars Negative Control siRNA; Qiagen). After transfection, DCs were rested for 2 h.

2D DC--T cell coculture assay {#s19}
-----------------------------

T reg and T conv cells isolated from OT-II mice by magnetic cell sorting were labeled with PKH-26 (red) and PKH-67 (green; both Sigma-Aldrich), respectively, according to the manufacturer's instruction. PKH-labeled T regs and T conv cells were cultured at a 1:1 ratio (5 × 10^4^ each) with unlabeled splenic DCs (5 × 10^3^) in 96-well non-tissue culture round-bottom plates as described before ([@bib31]). After 6-h culture in the presence of 1 µg/ml OVA~323--339~, cells were gently transferred to a glass-bottomed dish for confocal microscopy. The ratio of T regs to T convs per DC cluster was determined independently in 40 images by three blinded investigators.

3D DC--T cell coculture assay {#s20}
-----------------------------

DC2.4-CCL22^dox^ cells were harvested from stable in vitro cultures, and BMDCs were prepared from the bone marrow of WT or *Ccl22^−/−^* mice. DC2.4-CCL22^dox^ cells and BMDCs were labeled with PKH-67 (Sigma-Aldrich). T reg and T conv cells were obtained from WT or *Ccr4^−/−^* mice by magnetic cell sorting and were labeled with PKH-26 (Sigma-Aldrich). Subsequently, 2 × 10^5^ BMDCs or DC2.4-CCL22^dox^ cells and 10^6^ T reg or T conv cells were resuspended in a total volume of 100 µl containing 20 µl of a collagen gel master mix solution. To prepare the collagen master mix, 83 µl of 3 mg/ml rat tail collagen type I (Invitrogen), 10 µl M199 medium (Sigma-Aldrich), 2 µl distilled water, 2.1 µl of 1N NaOH, and 2.9 µl of 7.5% sodium bicarbonate were mixed to a total volume of 100 µl. The cell suspension was then placed in a CELLview cell culture dish with glass bottom (Greiner Bio-One) and polymerized to a gel for 45 min at 37°C. For the induction of CCL22 expression, DC2.4-CCL22^dox^ cells were pretreated with 2 µg/ml doxycycline. The gels were then analyzed by confocal microscopy in a live-cell imaging chamber (Leica TCS SP5) at 37°C and 5% CO~2~. Cuboids of 500 × 500 × 100 µm within the gel were filmed for 500 min with a lateral and vertical resolution of at least 256 × 256 pixels. Each cuboid consisted of 21 single-slice images with a distance of 5 µm, and images were obtained every 150 s. Recorded slices were transformed to a 3D model in Imaris (Bitplane AG). Videos were analyzed with a customized image-analyzing algorithm (Wimasis Image Analysis) for DC--T cell contacts. Briefly, red and green fluorescence channels were split, followed by a cell division algorithm to split cell clusters into individual cells. The positional information of the cells was then analyzed, and cells were considered to be in contact in case of an overlap of their pixels. For each frame, the percentage of DCs in contact with T cells was calculated.

Two-photon intravital microscopy {#s21}
--------------------------------

BMDCs were prepared from bone marrow of C57BL/6 mice and transfected with either control or CCL22 siRNA. Subsequently, DCs were pulsed with 1 µg/ml OVA~323--339~ peptide and labeled for 20 min at 37°C with 10 mM 5- and 6-(\[(4-chloromethyl) benzoyl\] amino) tetramethylrhodamine (CellTracker CMTMR; Invitrogen) or 7-amino-4-chloromethylcoumarin (Cell Tracker CMAC; Invitrogen). Control siRNA- and CCL22 siRNA-treated DCs (both 10^6^) were coinjected in 20 µl IMDM (with 10% FCS) containing 10 ng *Escherichia coli* LPS (Sigma) into the right hind footpad of C57BL/6 OT-II-Foxp3-GFP mice. 18 h after injection of DCs, animals received 100 µg anti-CD62L antibody (Mel-14) to inhibit lymph node homing during imaging, and the right popliteal lymph node was analyzed for 1 h by two-photon intravital imaging with an Olympus BX50WI fluorescence microscope equipped with a 20-fold magnification, 0.95-NA objective (Olympus) as described ([@bib27]). Image data collection was repeated every 20 s for 1 h. The 4D image dataset was processed using Imaris software (Bitplane) to create sequential 2D maximum-intensity projections. The absolute number of T reg contacts per DC over the time period of 1 h was quantified by individual inspection of each time point. Cellular interactions that were \<2 min or incompletely depicted spatially or temporally were excluded from the analysis.

OVA and DC vaccination {#s22}
----------------------

For OVA vaccination, mice were injected i.p. with 200 µl PBS containing 50 µg OVA (Sigma-Aldrich), 10 µg CpG 1826 (Coley Pharmaceutical Group), and 2 mg Imject Alum (Thermo Fisher Scientific) at weekly intervals. 1 wk after the second OVA injection, peripheral blood was collected to verify vaccination efficiency. For DC vaccination, BMDCs were generated from WT and *Ccl22^−/−^* mice, pulsed with 100 nM OVA~257--264~ peptide (InvivoGen), and activated with 6 µg/ml CpG 1826 for 4 h. WT or *Ccr4^−/−^* mice were injected i.p. with 4 × 10^5^ OVA~257--264~ peptide--pulsed activated BMDCs together with 10 µg CpG 1826 and 2 mg Imject Alum three times every second week. 1 wk after the last injection, peripheral blood or spleens were collected to analyze T cell responses.

Induction of DSS colitis {#s23}
------------------------

WT and *Ccl22^−/−^* mice received DSS dissolved in tap water at a concentration of 0.5% ad libitum for 7 d followed by 7 d of normal tap water. This cycle was repeated three times, and mice were sacrificed at day 42. The disease activity index described by [@bib9] including body weight, diarrhea, and the presence of occult or gross blood in the stool was applied to quantify the severity of colitis. Further, the length of the colon was used to determine disease activity. For hematoxylin and eosin staining, paraffin-embedded specimens were cut at 4 µm. The histological score was evaluated as described previously. Briefly, mononuclear inflammation or neutrophilic infiltration, crypt abscesses, crypt hyperplasia, and mucosal injury or ulceration were assessed. Each of the four criteria was graded (0, absent; 1, mild; 2, moderate; 3, severe), and the sum gave the final score.

In vitro migration {#s24}
------------------

Freshly isolated C57BL/6 splenocytes (1 × 10^6^) were put in the upper well of a 96-well Transwell migration plate (pore diameter 5 µm; Corning). 50 ng/ml of recombinant CCL22 (Peprotech) or supernatant from C57BL/6 and *Ccl22^−/−^* BMDCs cultured for 24 h was used as chemoattractant in the lower chamber. After 4--6 h, the migrated cells were harvested and analyzed by flow cytometry.

In vivo migration {#s25}
-----------------

C57BL/6 mice were subcutaneously injected (leg) with 4.25 × 10^6^ CpG-stimulated (6 µg/ml) and eFluor450-stained (5 µM, Cell Proliferation Dye; eBioscience) C57BL/6 or *Ccl22^−/−^* BMDCs. DC survival, costimulatory molecule expression, and migration into the ipsilateral inguinal lymph node were analyzed using flow cytometry 36 h after injection.

Statistics {#s26}
----------

All data are presented as mean ± SEM, and the statistical significance of differences was determined by the two-tailed Student's *t* test. Differences in tumor size were analyzed using two-way ANOVA with Bonferroni post hoc test and differences in survival by log-rank test. Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). P values \<0.05 were considered significant.

Online supplemental material {#s27}
----------------------------

Fig. S1 shows how CCR4 is expressed selectively by T regs. Fig. S2 shows that *Ccl22^−/−^* mice are deficient for CCL22 but proficient for CCL17 protein. Fig. S3 shows that DC-secreted CCL22 is a strong chemoattractant for T regs, siRNA efficiently knocks down CCL22 in DC, doxycyclin induces CCL22 in DC2.4-CCL22^Dox^ cells, CCL22-induced DC--T reg contacts depend on CCR4 expression by T regs, and that CD4 T cell immunity is enhanced in *Ccl22^−/−^* mice. Fig. S4 shows that WT and *Ccl22^−/−^* DCs do not differ in terms of in vivo migration, survival, costimulatory molecule expression, and in vitro cytokine production. Fig. S5 shows that CCL22 is strongly expressed in the tumor tissue of WT mice, but not in *Ccl22^−/−^* mice, and lymphocyte subpopulations in the tumor and lymph nodes are not altered in *Ccl22^−/−^* mice. Videos 1--9 show cocultures of DC with T regs in a 3D collagen gel. Video 1 and 2 show WT BMDCs cocultured with T regs. Video 3 shows *Ccl22^−/−^* BMDCs cocultured with T regs. Video 4 shows WT BMDCs cocultured with T convs. Video 5 shows *Ccl22^−/−^* BMDCs cocultured with T convs. Video 6 shows DC2.4 cells without doxycycline preincubation (i.e., without CCL22 expression) cocultured with T regs. Video 7 shows DC2.4 cells with doxycycline preincubation (i.e., with CCL22 expression) cocultured with T regs. Video 8 shows DC2.4 cells without doxycycline preincubation (i.e., without CCL22 expression) cocultured with T convs. Video 9 shows DC2.4 cells preincubated with doxycycline (i.e., with CCL22 expression) cocultured with T convs. Video 10 shows two photon in vivo imaging of OVA~323--339~-pulsed BMDCs pretreated with control or CCL22 siRNA in the lymph node of OT-II-Foxp3-GFP mice.
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